19 1 月, 2023

Want to Inspire Your Students to Make the Grade? Surprise Them with a Yowie!

NEW YORK, NY, Jan 19, 2023 - (ACN Newswire via SEAPRWire.com) - Teachers, are you looking for a way to welcome your class to an excellent new school year? Let Yowie help! The delicious, surprise-inside chocolate is the perfect way to start the new school year off right! Yowie World is looking to reward six lucky classes with 3 free boxes of Yowie! To enter the contest, just fill out your contact information at https://yowieworld.com/teacher-competition/. The winner will be drawn on February 16, 2023.Yowie Surprise-Inside Chocolate is made with 100% milk chocolate, sustainably sourced and Rainforest Alliance Certified and contains no GMOs or nuts - making it the perfect treat for the whole class! Yowie can be found at Coles supermarkets nationally, as well as IGA, Woolworths, Big W, The Reject Shop, and Kmart. Find Yowie near you at https://yowieworld.com/collect/#wheretobuy.The best part? When you use Yowie in the classroom, a teacher's science lesson for the day has a hands-on component. Each Yowie chocolate treat contains a life-like endangered animal collectible and comes with an informational leaflet inside, full of interesting facts about the hand-painted collectible. A treat and a science lesson in one! Plus, if you visit YowieWorld.com/Activities you'll find an impressive hub of teacher-approved activities that are perfect for new semester fun!Who are the Yowie? They include six characters: Rumble, Boof, Squish, Nap, Ditty and Crag. Each Yowie is responsible for protecting a different animal habitat and are friends with all the animals who live there. The Yowie are ALWAYS ready to jump into action to come to the defense of wild animals and the habitats they protect. Learn all about the Yowie at YowieWorld.com.Explore more of the wonderful world of Yowie on Facebook, or look for @YowieWorld on Instagram. You can also find easy, interactive, and educational craft projects and games on Yowie's YouTube channel and on Pinterest.About YowieYowie is best known for its flagship product, the Yowie surprise-inside chocolate. Each Yowie product is created in the shape of the Yowie characters and contains limited-edition collectible animal toys and a full-color leaflet featuring a picture of the real-life animal, its profile and level of endangerment. Yowie's social media channels and website allow collectors to learn more about the animals and their world while having loads of fun through games and competitions. The combination of tasty, clean-label treats, fun animal toys and a digital platform encourages kids to learn about the natural world and understand its need for protection. For more information visit www.yowieworld.com.Contact:Devin Mainvilledevin@kmkmedia.com(779) 221-3764SOURCE: Yowie Group Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)

23 12 月, 2022

Moshi Moshi Retail (SET: MOSHI) debuts on SET as it pursues aggressive growth to reign supreme in lifestyle product retailing

BANGKOK, Dec 22, 2022 - (ACN Newswire via SEAPRWire.com) - Moshi Moshi Retail Corporation (SET: MOSHI) is set to make a debut on the Stock Exchange of Thailand (SET) on 22 December, marking a new chapter of the flourishing business of Thailand's leading lifestyle product retailer.It follows an enthusiastic initial public offering (IPO) launch that saw its 75 million shares snapped up in a show of investors' confidence in the potential of MOSHI. By going public, the company is ready to embark on a major expansion that will see its chain stores rising to 165 by 2025, thus maintaining its leadership in Thailand's lifestyle product market.Mr. Sanga Boonsongkor, Chief Executive Officer of MOSHI, said the entry to the Thai bourse represents a major new milestone in the company's successful history. With the potential, competitive edge, and fundamentals as the major player in lifestyle goods retailing, MOSHI shares would gain the strength that attracts investors' attention, he stated. Currently, the company is involved with up to 12 product categories that meet the needs of customers. They are home furnishing, bags, stationery, plush dolls, fashion accessories, beauty products, apparel, cosmetics, IT equipment, toys, food and drink, and other categories such as fabric masks and COVID-19 Antigen Test Kit. Altogether, there are more than 22,000 stock keeping units (SKUs) in MOSHI's system.The products come in collection forms with new offerings being laid out in stores every month to make it appealing to buyers with colors and patterns designed by the company's in-house team and licensed cartoon characters such as Mickey Mouse, We Bare Bears, Winnie the Pooh, Snoopy, and Hello Kitty. The firm will use the proceeds from the fundraising for store expansion and investment in future projects. That includes the development of the original branches and improving the efficiency of the company's operations such as the development of supply chain systems and point of sale systems. In addition, MOSHI is pondering the establishment of stand-alone stores outside department stores in areas close to target customers such as community areas and schools, as well as opening franchised outlets.The target is for ramping up Moshi Moshi and GIANT outlets to 165 stores by 2025 from 101 operating as of 30 September 2022. Most of the outlets are located in leading department stores, hypermarkets, and local department stores nationwide.Mr. Sanga noted that the company would open two trial stand-alone branches in secondary provinces outside department stores at locations in communities, schools, and government centers. "We will study customer and shopping behaviors in secondary provinces to determine the product mix that is suitable for outlets in those localities, taking sale figures, and profit margins to analyze and determine the appropriate format of a franchise as MOSHI has set its sights on expanding its franchised operations in 2024."Mr. Pongsak Phrukpaisal, Managing Director of Kasikorn Securities PCL which serves as a financial adviser and underwriter for MOSHI allotment, said the company is ending 2022 with a high note, thanks to its listing on the SET. He said: "MOSHI is in the lifestyle product industry which is growing faster than the retail industry in general. "That is because lifestyle products are an indication of identity and therefore it has expanded according to the growth of the middle class.Moreover, MOSHI has advantages over competitors such as the management team with a long retail business experience and a good relationship with manufacturers and distributors both at home and abroad. Yet, MOSHI has many products that are only available at its stores. By being a Thai company with its own procurement and product development department, it has a good understanding of the market and the needs of the Thai people. As a result, the company has been able to constantly launch new products to respond to the demand trends of customers that change quickly. Meanwhile, MOSHI has an outstanding store design that makes it different from other operators' shops," he concluded.Visit https://www.moshimoshi.co.th/, [SET: MOSHI][SET: MOSHI/F][SET: MOSHI-R].Released for Moshi Moshi Retail Corporation for MT Multimedia Co LtdOnanong Pattaravejkul (Fah), T: +66 (0) 86-801-8888, E: ornanong.p@mtmultimedia.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

20 12 月, 2022

Korea Environmental Industry Association Revamps Environmental Technology & Product DB Search Portal EIDB

Seoul, Korea, December 20, 2022 – (SEAPRWire) – ‘EIDB’, an environmental technology product DB search portal in the domestic and international market by Korea Environmental Industry Association, is expected to have a service revamp in 2023 to present a new feature. It is the environmental technology product DB search portal that can satisfy the needs of the environmental industry with excellent environmental technology as well as the foreign buyers who are in need of environmental technology & product information in Korea. Since its establishment in 2014, with a continuous reorganization, it currently provides excellent companies & product information in the Korean environmental sector in 3 languages (Korean, English, and Chinese). At EIDB, company and product information are available. With a directory and company name search, 157 excellent environmental company information is available, and with a product name search, 336 excellent environmental product information is available. In particular, users can find appropriate companies & products with domestic and international certifications by selecting the type of business (manufacturing, environmental management agency, etc.) after choosing the category (water quality, atmosphere, waste, soil/groundwater, etc.). The example of the certification is as follows: KS for Korea, ISO9001, ISO14001 for overseas, UL (US), NSF(US), CE(Europe), RoHS (Europe), BS(UK), CCC(China), and JIS(Japan). Moreover, with the revamp in January 2023, it is expected to add a search function by piling information of 10,000 foreign environmental industry companies – making it possible to compare and analyze the product technology around the world at once. An official from Korean Environmental Industry Association stated, “Since it is possible to search products and technology with various conditions in line with the demand of domestic companies and government agencies, we expect that EIDB will become a distinguished search portal for buyers who are looking for excellent environmental technology and product. Media contact Company: Korea Environmental Industry Association Contact: Mr. Kyu-hyoung Kim Phone: +82-2-6933-9228 Website: http://keia.kr/dben/ SOURCE: Korea Environmental Industry Association The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)

2 11 月, 2022

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

TOKYO, Nov 2, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified post-marketing observational study condition required at the time of approval of antiepileptic agent Inovelon Tablets 100 mg and 200 mg (rufinamide) as an adjunctive therapy to other antiepileptic drugs (AEDs) for treatment of Lennox-Gastaut syndrome (LGS) has been cleared. In March 2013, the MHLW approved Inovelon as an adjunctive therapy with other antiepileptic drugs for tonic and atonic seizures associated with LGS showing insufficient response to other antiepileptics, with the following condition: "Because of the very limited number of subjects included in the Japanese clinical trials, the applicant is required to conduct a post-marketing observational study in all patients until data from a certain number of patients is accumulated after its launch in the market, in order to identify the background information of patients treated with the product and collect safety and efficacy data on the product in the early post-marketing period, and thereby take necessary measures to ensure proper use of the product." Based on the safety data in 702 patients and efficacy data in 495 patients submitted to the MHLW as the results of analyses of this all-case study, the MHLW has concluded that the all-case study was conducted properly and the necessary measures to ensure proper use of the product were sufficient to lift the condition. Eisai will continually strive to promote the proper use of Inovelon and provide information about the product, thereby making further contributions to increase the benefits to patients and their families.For more information, visit www.eisai.com/news/2022/news202275.html.Media Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

8 9 月, 2022

aCommerce Launches Price Intelligence for Real-Time Competitor Product Price Tracking

BANGKOK, Sep 8, 2022 - (ACN Newswire via SEAPRWire.com) - If your brand is competing on marketplaces in Southeast Asia, this one is for you! To compete effectively in what is dubbed the Southeast Asian marketplace price wars, it is crucial to know your brand's position in the market, with the key to establishing the right competitive pricing strategy, without sacrificing profit and growth, being to know your competitors' market prices.EcommerceIQ, the leading e-commerce management platform in Southeast Asia, introduced by the aCommerce team in 2019, is introducing its latest feature, built to give you the competitive advantage you need. Price Intelligence is a new comprehensive price tracking and monitoring tool that will help your brand stay updated on the market prices of similar products, and find the right balance between profitability and scale.Since Mega Campaign 3.3, aCommerce has been using Price Intelligence internally to QC campaign product prices. With the breakthrough Price Intelligence tool, there's no need to manually track your brand or your competitors' prices and sales performance on e-commerce marketplaces anymore, now Price Intelligence can do all of that for you in real-time.Price Intelligence is part of EcommerceIQ Market Insights' web-scraping technology. This new feature obtains real-time product data from marketplaces such as Lazada and Shopee, enabling you to have an overview of the entire pricing data in the market. The tool can see the fluctuations of your campaign products and the marketplace's performance - all from one single dashboard.Price Intelligence makes it simple to track the price and performance of the product groups similar to yours or your competitors and monitor campaign products, such as flash sales and pay-day sales. It also enables you to adjust your product prices for optimal revenue, create and monitor product categories that include items from specific brands and sellers, and track grey seller products.Price Intelligence is robust and easy to use. By simply adding the product URL from the Lazada or Shopee marketplaces, you will be able to view the information you need.Want to learn more? Visit https://ecommerceiq.asia/price-intelligence for more information.aCommerce (SET: ACOM) revolutionized e-commerce enablement with a cutting-edge platform & technology stack, EcommerceIQ. Proprietary software includes innovative omnichannel management software. We drive brands to achieve e-commerce goals with high-performance digital marketing, online store development & management, data & analytics, customer care, fulfillment & delivery services. Visit https://acommerce.asia.Released for aCommerce Group by MT Multimedia Co LtdWasana Wongsiri (Jiab), T: +66 84 359 0659, E: wasana.w@mtmultimedia.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

21 6 月, 2022

The Mechanism of Action of SinoMab’s Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.

HONG KONG, Jun 21, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, today announced that, on 10 June 2022, the mechanism of action of its flagship product SM03 (Suciraslimab) is successfully published in the Journal of Immunology, a reputable journal on immunology in the US (link to the paper: https://www.jimmunol.org/content/early/2022/06/10/jimmunol.2100820 ).Figure: Mechanism of Action of SM03 (Suciraslimab)The Journal of Immunology (the JI), founded in 1916 and managed and published by the American Association of Immunologists, is the world's leading peer-reviewed journal in the field of immunology, with a 5-year impact factor of 6.029 (Journal Citation Reports 2020), and publishes the latest immune-related findings in basic and clinical research in the field of immunology. It also publishes the latest research papers in the field of immunology, including cellular immunology, immunochemistry and molecular immunology, immunogenetics and immunomodulation, immunopathology and clinical immunology, immunopharmacology, microbial immunology, oncology and transplantation.The Company's flagship product SM03 (Suciraslimab) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA). The patient enrollment for the Phase III clinical trial in China has been completed by the end of 2021, with a total of 530 subjects recruited. The trial is a multi-centre clinical study led by Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, with clinical centres in 44 hospitals including Gulou Hospital of Nanjing University School of Medicine, the Second Hospital of Harbin Medical University and the First Hospital of Shanxi Medical University. The Company expects to lock the database at the end of June this year, read out the results of the Phase III clinical trial data in early August and will have biologics license application (BLA) in 2023. In addition, the development of Suciraslimab has also received support from the 863 Program, the "12th Five-Year Plan" and the "13th Five-Year Plan" for development of major new drugs, as well as the green channel for "prioritized review and approval" by the Center for Drug Evaluation (CDE). Previously, a phase II clinical trial led by Peking Union Medical College Hospital has demonstrated the efficacy and safety of Suciraslimab for the treatment of RA.The Company's flagship product Suciraslimab is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis. The core competitive advantage of this product over the standard therapies currently on the market is its novel and unique mechanism of action, which ensures that Suciraslimab is comparable to other products in terms of efficacy, while having significant advantage in terms of safety, which is a major concern for patients on long-term medication for autoimmune diseases.Under normal operation of human's immune system, B-cell receptor (BCR) pathway would be activated and create strong signals in response to foreign ("non-self") antigens and trigger a series of B-cell immune responses. To differentiate from our "self" antigens, our body would recruit molecules, like SHP-1, to inhibit or reduce BCR-induced signaling, thereby suppressing B-cell immune responses. We suggested that the recruitment of these molecules such as SHP-1 could be achieved by conversion of cis-binding CD22 to trans-binding CD22, thus suppressing relevant immune responses. Due to ageing or genetic predisposition, patients with autoimmune diseases such as RA are unable to convert cis-binding CD22 to trans-binding CD22, and are thus unable to recruit immunosuppressive molecules such as SHP-1 to inhibit or reduce the transmission of antigenic stimuli from B-cell receptors to B-cells, which then generate a series of immune responses, such as the secretion of large amounts of antibodies to attack autoantigens. Our flagship product, Suciraslimab, can facilitate the conversion of cis-binding CD22 to trans-binding CD22, forming a stable CD22 trans-binding structure, thereby restoring the tolerance of B-cells to autoantigens and inhibiting a series of relevant immune responses by B cells to attack the body.Historical data shows that Suciraslimab has a significant safety advantage compared to other products with comparable efficacy currently available in the market. Existing RA therapies include traditional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) such as methotrexate (MTX), biologic DMARDs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-6 receptors and other targets, as well as targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors and other small molecule drugs, all of which have played an important role in the remission of RA patients. However, most of the mechanisms of action of existing RA therapies will result in the depletion or death of B cells, which can have a series of side effects on human's autoimmune system, thus posing a long-term risk for patients with autoimmune diseases who require long-term medication, as the weakening of the immune system will naturally lead to the development of other debilitating diseases. In contrast, the mechanism of action of Suciraslimab is very different from that of existing therapies on the market. We only inhibit the B-cell related immune response by altering the binding of CD22 and recruiting related inhibitory molecules. Suciraslimab only inhibits the autoimmune response by regulating the function of B-cells and does not damage the B-cells and does not affect the normal function of B-cells in the immune system. Therefore, Suciraslimab has a significant safety advantage over other products currently available on the market.The autoimmune disease drug market has been touted as the next gold mine after oncology drugs. As the "king of drugs" in the world, Humira has topped the global drug ranking for eight years with sales of US$19.832 billion in 2020, making other drugs "bow down". Globally, pharmaceutical giants are focusing on the research and development of drugs in the rheumatic immune field, with the most prominent ones including Pfizer, Novartis, Johnson & Johnson and AbbVie, all with more than a dozen products in development or marketed in their respective pipelines. The global autoimmune disease drugs market is valued at US$113.7 billion in 2018 and is expected to reach US$152.3 billion by 2023 at a CAGR of 6.0%. The market for autoimmune disease drugs in China is expected to grow from RMB13.4 billion in 2018 to RMB37.7 billion in 2030 at a CAGR of 23%. Driven by the global trend of innovation, R&D in rheumatic immune field in China is also gaining momentum. As a leading pharmaceutical innovator in China, Hengrui Pharma has also adopted a strategy of early development, target optimization and expansion of indications in the rheumatic immune field, aiming to fully capitalize on the rapid development of the autoimmune disease market in China. This indicates that SinoMab's mission and vision to become a global leader in innovative therapies for immune and other debilitating diseases are in line with the development trend of the entire pharmaceutical industry. In the foreseeable future, it is believed that SinoMab will help more and more patients suffering from autoimmune diseases and become a leading global biopharmaceutical company focusing on innovative therapies for autoimmune diseases.In addition to its flagship product Suciraslimab, the Company's core product SN1011 has an expanding scope of indications and continues to receive regulatory approval for new drug applications in China and abroad, and also expects to rapidly initiate Phase II clinical trials for pemphigus vulgaris (PV), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and neuromyelitis optica spectrum disorder (NMOSD) this year. SinoMab also dosed first healthy subject in Phase I clinical trial of its major product SM17 in the U.S. in June 2022. By targeting upstream mediators of the Th2 inflammatory cascade, SM17 is able to control inflammatory airway diseases such as asthma caused by the immune cascade at a relatively early stage and is expected to benefit a large number of patients with severe uncontrolled asthma by satisfying unmet medical needs.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for RA in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

31 3 月, 2022

VOOPOO and ZOVOO Shine as Joint Exhibitors at the 2022 Malaysia Vape Show

SHENZHEN, CHINA, Mar 31, 2022 - (ACN Newswire via SEAPRWire.com) - The two-day Malaysian Vape Show (MIVAS) concluded successfully on March 27. The show brought together more than 100 exhibiting brands worldwide and attracted over 5000 professional visitors.As two of the most influential VAPE brands in Southeast Asia, VOOPOO and ZOVOO attracted the most visitors to the exhibition hall with their unique booth design, simple brand image, and amazing product experience.As the pioneer of technological change in the industry, VOOPOO and ZOVOO jointly exhibited at the 2022 MIVAS, discussing the future development trend of the industry and the upgrade and innovation of product experience with many partners, fans and users, and business competitors.Joint exhibition attracts widespread attentionAs two of the most influential VAPE brands in Southeast Asia, VOOPOO and ZOVOO attracted the most visitors to the exhibition hall with their unique booth design, simple brand image, and amazing product experience. Many local fans lined up in long queues to participate in the on-site interaction and product experience.At the same time, many local distributors and retailers appreciated VOOPOO and ZOVOO's extensive product lines, especially VOOPOO's newly developed ARGUS GT 2 and ZOVOO's DRAGBAR5000 and DRAGBAR5000C sugar-free concept products. They kept asking for and showing strong interest in cooperation.The feedback from the dealers on site said, "The VOOPOO ARGUS GT 2 is extremely powerful with its 200W power and stunning triple defense design. ZOVOO's product design is bold and innovative, taking into account not only the user's feelings but also the aesthetic design, and the price is quite competitive."The pinnacle of brand-new research and developmentThe ARGUS GT 2, VOOPOO's first MOD product of 2022, inherits the classic style of the ARGUS GT and brings the best of technology and design to the show floor, which numerous vapers have well received since its launch at the show.ARGUS GT 2 has a sense of technology and design from appearance to usage. It is designed with leather and metal, and every texture is solid and powerful. From the distinctive metal body to the finely crafted leather texture, every detail is a classic. The new ARGUS GT 2 combines luxury craftsmanship and technology for a comfortable grip and a solid visual impact.It has up to 200W high power constant voltage stable output, IP68 tri-proof design, innovative volcano air channel mouth leak-proof design, GENE.TT 2.0 chip, 6.5ml large capacity, 3A TYPE-C fast charging, etc. The newly developed MAAT TANK NEW atomizer has defined a new height of experience. The unveiling of the new ARGUS GT 2 has also amazed the audience and has been well received.ZOVOO DRAGBAR innovative sugar-free productsAs a disruptor in the overseas Pod market, ZOVOO launched the industry's first sugar-free disposable e-cigarettes, DRAGBAR 5000 and DRAGBAR 5000C, which innovatively use ethyl malt alcohol to provide sweetness of the vape oil. As an alternative to cane sugar certified by authorities in many countries, ethyl malt alcohol ensures sweetness without additional sugar intake, effectively avoiding the harmful effects of sugar addiction on the body. It is a great choice for those who are sugar-free or less sugar-intensive.As ZOVOO's flagship product, the DRAGBAR range has gained attention and interest from users worldwide since its inception. The use of ethyl malt alcohol in ZOVOO is not only a demonstration of ZOVOO's deep understanding of user needs but also a new definition of disposable e-cigarettes. It will become a major milestone in the industry and open up a new era of sugar-free e-cigarettes.It is understood that the ZOVOO team discovered the spitting and bursting problems of disposable e-cigarettes after surveying 3,000 global users. After a year of research and tens of thousands of trial tests, the ZOVOO team found a solution. ZOVOO's mesh coil dramatically improves the atomization performance of disposable e-cigarettes and solves the spitting and bursting problem of disposable e-cigarettes. Meanwhile, DRAGBAR 5000 employs silicone preservation technology to lock in freshness extremely well and guarantee its fullness.The ZOVOO team's optimization of product details and taste guarantee has made ZOVOO DRAGBAR popular among a wide range of users in North America, Europe, Southeast Asia, and other regions.In future, VOOPOO and ZOVOO will always adhere to the original intention, sticking to the "user first" product concept. They will pursue innovation and breakthroughs in technology and continue to launch a richer and more diversified product selection, committed to providing a safer and more enjoyable product experience for consumers worldwide. They will work with partners to continue to layout offline channels at home and abroad and provide partners with a full range of support solutions in the product, logistics, branding, and marketing to build an innovative and diversified ecological cooperation.WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.Media contact:Wind Chen, VOOPOOE: wind.chen@voopoo.comU: https://www.voopoo.com/T: +86-18718743237 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

31 3 月, 2022

Mengniu Announces 2021 Annual Results

HONG KONG, Mar 30, 2022 - (ACN Newswire via SEAPRWire.com) - China Mengniu Dairy Company Limited and its subsidiaries (together as "Mengniu" or the "Group") (Stock Code: 2319), a leading dairy product manufacturer in China, has announced its audited annual results for the year ended 31 December 2021.In 2021, Mengniu seized the development opportunities in the dairy product industry through continuous product innovations and upgrades, rebranding efforts, and expanding online and offline channels for omnichannel development, leading to revenue growth that once again exceeded expectations. For the year ended 31 December 2021, the revenue of the Group amounted to RMB88,141.5 million, representing a year-on-year increase of 15.9%, reflecting the strength and resilience growth of the Group. Benefitting from the increase in revenue and operating efficiency, profit attributable to owners of the Company increased by 42.6% year-on-year to RMB5,025.5 million.2021 also marked the commencement of the Group's five-year strategic plan, "Creating a New Mengniu", which is of great importance to its future. While the prolonged COVID-19 epidemic continued to impact the global economy adversely, Mengniu delivered remarkable results and achieved steady overall revenue growth due to a combination of effective epidemic control in China, policy support for the industry, and collective efforts of all the Group's employees. Each of the business segments also saw robust growth, laying a solid foundation for achieving its five-year strategic goal and becoming one of the preferred dairy brands for Chinese consumers. In 2021, the Group continued to drive product innovation, brand elevations, and channel expansion for the room temperature, chilled, and fresh milk businesses, leading to revenue growth of 12.9% from the same period last year to RMB76,514.4 million from the liquid milk business.High-End Room Temperature Brands Accelerated Faster Than the IndustryBenefiting from the diversified demand of consumers, Mengniu's room temperature product business continued to innovate throughout the year with product upgrades, branding enhancements, strengthened sales channels, and an improving supply chain foundation. The segment recorded five straight years of strong double-digit growth, resulting in a continued increase in market share. In particular, the growth of Milk Deluxe and Mengniu pure milk products was significantly higher than the industry. Since its establishment in 2005, Milk Deluxe has continuously focused on innovation and product upgrades, brand building, and "better" communication with consumers. It now is the first individual product in the global dairy industry with sales exceeding RMB30 billion in 2021.Innovative Chilled Products and Ice Cream Businesses Outperformed the MarketMengniu's chilled product business continued to record volume growth, outperforming the market significantly and expanding its leadership position during the year. The chilled products segment has ranked first in the industry for seventeen consecutive years in terms of market share. In 2021, the Group took advantage of the rapidly growing zero-sugar product category supported by the "Three Reductions & Three Kinds of Health" campaigns launched by the Chinese government, and met the growing demand for lower sugar intake of consumers by introducing the Champion zero sucrose and sugar-reduced product. In addition, Yoyi C launched a new reduced-sugar product and a new zero sucrose product. At the end of the year, Yoyi C also launched a probiotic powder product with 100 billion high compound probiotics setting a new industry benchmark. During the year, the Champion and Yoyi C brands were further heightened through product and sales enhancement. With respect to sales channels, Mengniu explored and expanded new sales models and channels proactively. The chilled product business unit collaborated with Sam's Club for the first time to provide customized yogurt products and develop a new business model exclusively for direct sales. These new customized yogurt products became the annual major product of Sam's Club immediately following its launch and have ranked among the top of the best-selling list for e-commerce chilled milk products.As the consumption upgrade trend continues, innovation of ice cream products has leaned towards more high-end, healthy, and trendy products. The rapid growth of in-home consumption of ice cream products and the e-commerce and new retail channels further promoted the growth of ice cream products. In 2021, the entire product lines of brands such as Suibian, Mood for Green, and Deluxe were modernized and renewed. The Group accelerated the development of new retail channels through deep channel cultivation, further expanding network coverage and strengthening sales terminal control, driving strong growth in the ice cream business. To accelerate the business expansion in the Southeast Asian market, the Group acquired Aice, a leading ice-cream brand in Southeast Asia at the end of March 2021. In 2021, the revenue from the ice cream business increased by 61.0% from the same period last year to RMB4,240.2 million.Fresh Milk and Cheese Businesses Maintained High Growth MomentumThe fresh milk industry maintained rapid growth in 2021, leading the overall liquid milk industry. Mengniu's fresh milk business has been developing strongly by improving the "freshness" in all stages of the supply chain from the meadows, R&D, processing, logistics to cold chain distribution. The segment also continues to benefit from its solid execution of strategies such as reinforcing its brand, expanding sales channels, and enhancing its supply chain deployment. Mengniu has driven rapid revenue growth of its dual-core brands Shiny Meadow and Modern Meadow and further increased its leading position and market share in the high-end fresh milk market.In 2021, grasping the growth opportunities in the cheese industry, the Group focused on children's cheese sticks, cheese snacks, cheese, and butter for family consumption, and provided dairy product solutions to customers in the foodservice channel. By exploring new consumption scenarios, the cheese business grew rapidly in both the retail and foodservice sectors. On 9 July 2021, Mengniu became a substantial shareholder of Shanghai Milkground Food Tech Co., Ltd. (600882.SH) ("Milkground"). Moving forward, both the Group and Milkground will be able to create synergies through shared resources and reap the benefits from the enormous potential in the domestic and global cheese market.Accelerated the Development of New Segments in the Milk Formula BusinessFor the milk formula business, Yashili, the domestic milk formula platform of the Group, introduced a variety of adult functional milk powder products and expanded the coverage of functional products, focusing on high-end development and accelerating the development of new market segments. In addition, the existing infant formula products were continuously upgraded to refresh brand images, whilst Bellamy's adhered to its brand positioning of "True Organic". Through market segmentation and expansion of sales channels, the revenue from the milk formula business increased by 8.2% from last year to RMB4,949.1 million.Proactively Fulfill Social Responsibilities to Lead A Green Transformation and Create A Net-Zero Emission FutureOver the years, Mengniu has been highly proactive in fulfilling social responsibilities to create a more responsible Mengniu. The Group's efforts have been highly recognized through numerous awards, including the "China Charity Award", the highest government award in the philanthropic field of China for our outstanding performance in the community in the fight against the COVID-19 epidemic. In addition, Mengniu was also awarded "The State Scientific and Technological Progress Award" for its Key technologies for safety control and quality improvement of milk and dairy products.In line with the sustainable development goal of the United Nations, and as part of the strategy of "Creating a new Mengniu by 2025", Mengniu unveiled its new 2025 GREEN sustainable development strategy and developed a set of industry-based "High-quality Green development" solution models, setting the benchmark for sustainable development. Mengniu has actively responded to the national goal of "carbon neutrality" and pledged to be the first to achieve carbon neutrality in the dairy industry. The Group will announce its carbon emission reduction targets and roadmap in 2022. As of the end of the year, Mengniu had 22 factories rated as being a "National Green Factory" by the Ministry of Industry and Information Technology.Mr. Lu Minfang, Chief Executive Officer of Mengniu, said, "We are now confidently moving towards the mission of "Creating a new Mengniu" by 2025 as we strive to continue being Chinese consumers' first choice amongst dairy brands. We will also become a "FIRST Mengniu", one that is beloved by consumers, more international, socially responsible, culturally strong, and digitally transformed by 2025. Based on the strengths of our five core capabilities, we will combine our development goals with promoting the high-quality development of the industry, leading industry upgrades and transformations, creating sustainable value for all stakeholders, making new and more substantial contributions to the long-term development of the dairy industry in China.About China Mengniu Dairy Company LimitedChina Mengniu Dairy Company Limited and its subsidiaries manufacture and distribute quality dairy products in China. It is one of the leading dairy product manufacturers in China, with MENGNIU as its core brand. Mengniu offers diverse products including liquid milk products, ice cream, milk formula and cheese. Mengniu ranked as "Global Dairy Top 10" in 2021, and placed 31th on BrandZ(TM)'s list of most valuable Chinese brands, TOP10 of brand contribution in 2020. Mengniu also made it again among Brand Finance's list of the top 500 most valuable brands of the world in 2020. As at the end of 2021, the Group's annual dairy production capacity reached 10.89 million tonnes. In March 2014, Mengniu became a Hang Seng Index constituent, making it the first blue chip Chinese dairy product manufacturer. In March 2022, Mengniu was included as a constituent of HSI ESG Enhanced Index and HSI ESG Enhanced Select Index. For more information, please visit www.mengniuir.com.For Investors and Media Enquiries:Christensen AdvisoryVivian WangTel: +852 2232 3978E-mail: vwang@christensenir.comSuri ChengTel: +86 185 0060 8364E-mail: Scheng@christensenir.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

13 1 月, 2022

Zzogri Announces Its Unrivaled Technology

Seoul, Korea, January 13, 2022 – (SEAPRWire) – ‘Zzogri’ of Edenview Inc., specializing in the production of convenience equipment for work in Korea, has been garnering global attention with its unrivaled technology. It has been recognized for its expertise and ability to develop new market by actively exporting to Japan, the U.S., Canada, and European countries and playing a role in creating the Korean Wave. In particular, Japanese customers praise for its high-quality and exceptional features that help continuous export of the product by local Japanese brand called ‘ジョグリ’ (Zzogri). Zzogri is a convenient chair for the user who needs to squat while working. It has become a must-item since more than 3 million Korean farmers use three or four chairs every year. In particular, President’s wife Kim Jeong-sook used it when she was engaged in volunteer work in Cheongju, Chungcheongbuk-do Province, in 2017. The Zzogri of Edenview is very easy to attach and detach as it is worn like a belt around the waist. In addition, its safety belt doesn’t make the users fall on their buttocks since its sitting cushion is fixed on their body to secure its safety. Due to its lightweight and portability, it was selected as an excellent invention by the Korean Intellectual Property Office. Zzogri has gained much popularity among Korean farmers. That explains why the product has been distributed to farmers through the public institution’s support project to prevent farmers’ musculoskeletal diseases. In addition, it received the Grand Award in the category of agricultural equipment for the convenience at ‘The best brand for empathy in Korea award’ for two consecutive years in 2017 and 2018. An official of Edenview said, “Our product is excellent for overseas gardeners and auto mechanics. We’re planning to advance into more countries in the future. Also, we’re actively looking for various investors and overseas sales agencies.” Media Contact Company: EDENVIEW CO., LTD. Contact: Kim, Jin A Email: edenview@zzogri.com Phone: +82-62-652-2587 Website: http://zzogri.com SOURCE: EDENVIEW CO., LTD. The article is provided by a third-party content provider. SEAPRWIRE makes no warranties or representations in connection therewith. Any questions, please contact cs@SEAPRWIRE.com Sectors: Top Story, Daily News SEAPRWIRE (www.seaprwire.com) offers newswire service in Southeast Asia (Indonesia, Thailand, Vietnam, Singapore, Malaysia, Philippines & Hong Kong )

11 1 月, 2022

CEFC Financial Proposes Change of Company Name to Virtual Mind Holding Strategically Transforming to be an All-rounded Trendy Apparel Product Manufacturer

HONG KONG, Jan 11, 2022 - (ACN Newswire via SEAPRWire.com) - CEFC Hong Kong Financial Investment Company Limited ("CEFC Financial", together with its subsidiaries, "the Group"; stock code: 1520.HK) is pleased to announce its proposed change of company name to "Virtual Mind Holding Company Limited", to better align with the Group's business development strategies. Meanwhile, the Group has entered into a strategic cooperation agreement ("cooperation agreement") with Qingdao Weiding Sports Supplies Company Limited ("Qingdao Weiding") in trendy apparel markets, and appointed the senior designer of the world luxury product brand LVMH Group Dr. Zhou Yibing ("Dr. Zhou") as Chief Creativity Officer ("CCO"), striving to become an all-rounded trendy apparel product manufacturer. The proposed change of company name is subject to the approvals of shareholders and the Registrar of Companies in the Cayman Islands.Establishment of strategic cooperation relationship with Qingdao Weiding to seize the opportunities in trendy apparel market in the PRCThe recent development in the apparel industry has been shifting its focus towards the market segment in the younger generation with trendy culture. Therefore, the Group aims to capture this opportunity with a vision to develop trendy culture apparel products and has been actively seeking new business opportunities to expand the Group's design, manufacturing and trading of apparels business in order to diversify from its focus of manufacturing private label women apparels products to become an all-rounded trendy apparel product manufacturer, tapping into the men and young adults markets. To achieve its strategic moves and pursuant to the cooperation agreement , the Group and Qingdao Weiding will (i) carry out in-depth research and development on trendy apparels' intellectual property ("IP") and trendy apparels products; (ii) coordinate the resources, sales channels and marketing activities to increase market competitive advantages; (iii) share customer information, recommend customers to each other and provide services to each other's customers for product introduction and promotion; and (iv) jointly develop new products, new businesses and new business models in the trendy apparel market. Both parties shall promote and refer to each other (i) third-parties fashion apparel orders; (ii) application of non-apparel trendy brand related products in each other's branded products; (iii) application of branded products of the parties in cross-over collaboration with other branded products. A referral fee shall be payable by the referee to the referrer based on the successful contract amount of the apparel order, on the conditions that a certain amount of sales and a corresponding gross profit margin are achieved. Qingdao Weiding shall promote to the Group its own brand "Weiding" orders and offer a discounted contract price to the Group based on the final retail price.Qingdao Weiding is principally engaged in the research and development, production and sales of trendy and sports apparel and accessories products. It has been granted the famous trademarks of Shandong Province award and Qingdao award and has obtained the ISO9001 qualification certification. The cooperation would enable the Group to leverage the design experience and market knowledge of the management team of Qingdao Weiding on the sports apparel in both women's and men's markets and expand the Group's exposure in these market segments. The Group could also share the customer information and have an in-depth understanding on the markets and access to new sales channels. Moreover, the Group could exploit the IP rights owned by Qingdao Weiding in developing the cross-over trendy apparel products which could increase the variety of the Group's products to seize the opportunities in the trendy apparel markets in the PRC.Appointment of Dr. Zhou Yibing, senior designer of LVMH Group, as CCO to create unique fashion apparel productsIn addition, the Group has appointed Dr. Zhou Yibing ("Dr. Zhou") , the senior designer of LVMH Group, as the Group's CCO. Dr. Zhou has served as a designer of Givenchy since 2018 and she was promoted to senior designer in 2020 and double WRTW-star senior designer in 2021. Prior to joining Givenchy she worked as a designer in Balmain Group and was responsible for fancy jewelry in Buccellati Italy. Dr. Zhou will be responsible for managing the product design team of the Group through the recruitment of a team of young and talented designers, with the aim of capturing the market opportunities in the younger generation, developing own brand trendy culture products including apparels, cross-over products with other brands in order to enhance the Group's strategic move to re-foucs from its women apparel products to all-rounded trendy apparel and other accessories products for men, women and young adults.The Group has been engaged in the apparel design business for over 20 years and is committed to designing and manufacturing high-quality fashion products. In view of the enormous potential in the trendy apparel market, the management of the Group plans to progressively expand the Group's trendy apparel manufacturing business in future and strategically transform its business from private label women's apparel manufacturer to an all-rounded trendy apparel product manufacturer. The management is pleased to establish cooperation with Qingdao Weiding and has invited Dr. Zhou to join its product apparel design team. These moves will complement the Group's overall strategic development blueprint and enhance its operating strategy. Leveraging the technology, experience and sales channels accumulated by the Group in the design and manufacturing of apparel business, the Group is expected to further expand its market segments on top of its original business and develop a variety of new apparel and apparel-related product offerings, thereby enhancing the Group's profitability and brand impact to create long-term returns for shareholders.About CEFC Hong Kong Financial Investment Company LimitedCEFC Hong Kong Financial Investment Company Limited (1520.HK) is principally engaged in (i) design, manufacturing and trading of apparel; and (ii) provision of money-lending business. The Group's apparel operation is classified into two categories, namely, private label products and own brand products. Private label products are those designed and manufactured under the private labels owned or specified by the Group's customers, while own brand products are those designed and manufactured under the Group's proprietary labels. The Group's production plant is located in Jiaxing in the PRC with most apparel products exported to the U.S. The U.S. market is the principal market for Group's apparel operation.For more details, please visit www.cefcfi.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

19 12 月, 2021

Sirnaomics Ltd. Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Dec 19, 2021 - (ACN Newswire via SEAPRWire.com) - Sirnaomics Ltd. ("Sirnaomics" or "Company", stock code: 2257.HK), the RNA therapeutics biopharmaceutical company withs strong presence in both China and the U.S., today announces the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK").Sirnaomics plans to offer an aggregate of 7,540,000 Offer Shares under the Global Offering (subject to the Over-allotment Option), consisting of 6,786,000 International Offer Shares (subject to reallocation and the Over-allotment Option) and 754,000 Hong Kong Offer Shares (subject to reallocation), at a price range between HK$65.90 and HK$72.70 per share.The Company will start its public offering in Hong Kong at 9 a.m. on December 20, 2021 (Monday) and end at 12 noon on December 23, 2021 (Thursday). Dealings in shares on SEHK are expected to commence on December 30, 2021 (Thursday), with the stock code of 2257.HK in board lots of 50 shares each.China International Capital Corporation Hong Kong Securities Limited is the Sole Sponsor, Joint Global Coordinator and Joint Bookrunner. The Hongkong and Shanghai Banking Corporation Limited, Nomura International (Hong Kong) Limited, China Merchants Securities (HK) Co., Limited, and China PA Securities (Hong Kong) Company Limited are the Joint Global Coordinators and Joint Bookrunners. The Global Offering introduced Kunming Jiashiqing and Innoforce Pharmaceuticals as the cornerstone investors. Strong presence in both China and the U.S., with product candidates in a broad range of therapeutic areas Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the U.S which is also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics. The Company's product pipeline has over a dozen product candidates for a range of therapeutic indications across rare and large market diseases covering oncology, fibrosis, medical aesthetics, antiviral, cardiometabolic disease and other fields. Its product candidates currently span all stages between preclinical research and IND-enabling studies to Phase I and Phase II clinical trials, creating an enriched portfolio and an extended timeline of product candidates. The Company utilizes the complementary regulatory systems in China and the U.S. to accelerate development and attain regulatory approvals, including by pursuing candidates and indications where orphan drug designation can be achieved in the U.S., which can shorten the review period from 1-2 years to 6-12 months. Significant advantages in proprietary and novel drug delivery technology platform to improve the continuous development of RNA therapeutics and mRNA vaccines The proprietary delivery platforms for administration of RNA-based therapeutics are the foundation of the product pipeline of Sirnaomics, and the related proprietary PNP and novel GalNAc delivery platforms confer advantages over conventional delivery platforms. The Company believes its highly innovative RNAi delivery platforms set Sirnaomics in a class by itself. The PNP delivery platform allows delivery of both siRNA and mRNA to diseased cells via local or systemic administration, providing distinct advantages in low toxicity, easy manufacturing and the capability to reach many targeted organs and certain cell types. The results of Phase IIa clinical trial in oncology validates both the effectiveness of its PNP delivery platform and the therapeutic targets for isSCC, positioning the Company for accelerated development of other pipeline products using the same PNP delivery platform. The Company's core product candidate STP705, as well as other clinical stage product candidate STP707, and at least eight other preclinical product candidates utilize the PNP delivery platform. RNAimmune, a controlled subsidiary of Sirnaomics, also applies PNP delivery platform, and a related proprietary delivery platform based on polypeptide-lipid nanoparticles (PLNP), to formulate mRNA-based therapeutics and vaccines. Besides, the proprietary GalNAc RNAi delivery platforms, GalAhead(TM) and PDoV-GalNAc of Sirnaomics, enable specific delivery to liver hepatocytes with enhanced endosome escape properties and dual siRNA target design, resulting in high potency. The GalNAc-conjugate delivery platforms rely on peptide conjugates and/or unique RNA structures that allow knockdown of single or multiple distinct mRNA targets. The GalAhead(TM) delivery platform conjugates GalNAc moieties to unique RNAi trigger structures that can target one or more genes simultaneously. In PDoV-GalNAc RNAi platform, GalNAc is conjugated to a peptide linker and up to two siRNAs are also conjugated to the same peptide. The Company has three pipeline products utilizing its GalAhead(TM) delivery platform quickly approaching IND-enabling studies. The Company is currently developing several delivery platforms, including different approaches of siRNA/chemo-drug conjugates, peptide ligand tumor targeting and respiratory virus treatment via airway delivery. The Company is committed to investing in research and development in its advanced delivery platforms to enable the expansion and refinement of the range of organs and tissues that can be targeted by its pipeline products and to drive future growth opportunities. Potential first-in-class dual-targeted RNAi therapeutics for the effective treatment of cancer and fibrotic diseases STP705 and STP707 are the Company's lead product candidates, which are dual-targeting RNAi therapeutics based on more than a decade of experience researching TGF-beta1 and its synergistic effects when combined with COX-2 for tumor suppression and fibroblast. Currently, the mechanism of action for both TGF-beta1 and COX-2 in tumor biology and fibrotic disease is widely recognized. Both act as gatekeeper genes, where their inhibition blocks a downstream cascade of events that would otherwise lead to tumor cell proliferation, survival, invasion, angiogenesis and immune evasion. Moreover, by silencing TGF-beta1 and COX-2 simultaneously, Sirnaomics' product candidates achieve a higher potency than inhibiting either alone. The therapeutic effectiveness for STP705 has been confirmed by the successful Phase IIa results of Sirnaomics. No currently marketed drug product utilizes this molecular targeting approach. Comprehensive intellectual property portfolio driven by independent research and development capability Since inception, Sirnaomics has set strategic focus in developing innovative technologies and seeking protection using a comprehensive strategy for filing for patent protection across markets and technology areas. All of the pipeline products have been developed primarily in-house in its research centers in the U.S. and China such that the development of its product candidates is initiated and directed by in-house team and the Company does not rely on third party in-licenses for its product pipeline. As of 10 December, 2021, Sirnaomics owned 20 issued patents (9 in China, 9 in the U.S. and 2 in Europe) and have filed 119 patent applications that are currently pending (19 in China, 43 in the U.S., 6 in Europe, 8 under the Patent Cooperation Treaty and 43 in other jurisdictions). Sirnaomics' patent claims cover the siRNA and mRNA drug composition in its pipeline products, delivery platforms, modes of delivery for pipeline products, manufacturing technology, and methods of use in various therapeutic areas. Senior management and experienced outside intellectual property counsels collaboratively craft the globally-integrated intellectual property strategy with an eye to broad protection in China, the U.S., Europe and other key jurisdictions. In addition, based on the Company's independent research and development capabilities and the development potential of its core candidate product, STP705, Sirnaomics has been cooperating with other well-known Chinese pharmaceutical companies in recent years, including Innovent, Shanghai Junshi, Walvax and Guangzhou Xiangxue, etc., covering the therapeutic areas of multiple cancer, influenza virus, and hypertrophic scar. Seasoned management team and world-class industry expertise Sirnaomics is led by the management team with deep experience and capabilities in discovering, developing, manufacturing and commercializing RNA therapeutics. Dr. Patrick Y. Lu, Founder, Chairman of Board, President and CEO, has over 28 years biopharma research and development experience in China and the U.S. Dr. Lu has led the teams building up a robust technology platform and an enriched RNA therapeutic product pipeline. Dr. Lu is an inventor on 53 patents with over 55 authored scientific publications, and has been recognized with multiple awards and grants in China and the U.S. for his innovative research and entrepreneurship. In addition, the management team and scientific advisory board have on average more than 20 years of pharma research and development experience at the world's leading pharmaceutical companies and research institutions in China and the U.S. Looking forward, Sirnaomics is committed to becoming a fully-integrated international biopharmaceutical company. Leveraging its deep experience in RNA therapeutics and novel delivery platform technologies, the Company will advance the development of innovative therapeutic modalities for the treatment of a broad range of disease states and strengthen its intellectual property position, accelerate the commercialization of its core product candidate STP705, develop and commercialize a diverse portfolio of transformative RNA products in a broad range of therapeutic areas, including both rare diseases and diseases with large patient populations. In additions, the Company also plans to expand its internal GMP manufacturing capabilities, develop commercialization abilities, and selectively pursue synergistic collaboration opportunities to maximize the potential of its clinical product candidates to rapidly discover, develop and commercialize a portfolio of transformative therapeutics and vaccines for patients suffering from a wide range of both rare and large market diseases. About Sirnaomics Ltd.Sirnaomics Ltd.("Sirnaomics" or "Company", stock code: 2257.HK) is an RNA therapeutics company with product candidates in pre-clinical and clinical stages that focused on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. The Company is the first clinical-stage RNA therapeutics company to have a strong presence in both China and the U.S, and also the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics for its core product, STP 705.This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Sirnaomics Ltd. For further information, please contact: Porda Havas International Finance Communications GroupEmail: sirnaomics.hk@pordahavas.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

10 12 月, 2021

Writing a Press Release; Effectively Connecting with Your Audience and Keeping Them

HONG KONG – Over the years, there have been significant changes in the world of marketing, communications, and sales. Don’t kid yourself; the press release distribution fits right in this category as well. Specifically, we are talking about the manner a business communicates with its audience. This style has changed over the years. At NovationWire, we feel that this information is relative to the tone a business takes when writing a press release. We mention this only because of the volume of press releases we have seen written in a fashion that would be applicable ten plus years ago that is no longer relevant today. It can even repel your audience. Back in the day, businesses would write marketing and communication material in a tone where the hard sale was the push. This type of style is no longer applicable and will quickly push your audience away. When you are writing your press release, depending on the subject at hand, if you are trying to draw in new customers for a product or service, you must take the angle of how you are solving a problem for them. Don’t list all the features that your product or service may offer; instead, explain how your product or service can help someone out and relieve a particular pain. A weak example might be a small home office sized product that assembles and seals boxes to hold widgets. Explaining how time is money and how you, as a business owner, could have that time better spent elsewhere to grow your business takes away a pain of time spent packaging widgets. (More on this through a book recommended to us “The 1-Page Marketing Plan” by Allan Dib. Although this may be a book on ‘marketing,’ the same principles still apply to the tone you take in your press release. Gaining trust from your audience and followers is more significant than you may imagine. You cannot force your product or service upon people; you need to gain their trust and let them come to you. One right way to do this is by regularly sending press releases to the media, as long as you have something newsworthy to share. If the news you are submitting is about your industry, eventually, you start to gain trust from your audience, which may include journalists, bloggers, and your customers. The reason this is important is because of this; Although a journalist may not publish your article immediately, they may take one of two actions. First, they may stick your press in their back pocket, knowing that they have a segment coming up months later where it will be suitable. At NovationWire, we have heard of stories published as much as five months later. The second action a journalist may take is this. They are looking to do an article on a particular subject. The journalist may not use one of your press releases directly because they have seen your regular publications in the news (sure – they may not have used them, which is fine). They recognize you as either an industry expert or leader in your industry. Seeing you as an industry expert means when they do write their article, they may come to you for information as the industry expert and quote you and or your business within their writing material. This type of earned media is golden, a milestone that many business owners strive to achieve. First, it is not biased, it is written entirely by a trusted source, and readers see your name and or company and associate this trust. The instant trust and recognition for your brand is not something that can be purchased. The value in this type of earned media far outweighs any purchased advertising spot. The key is consistency with excellent value content and not using a hard sell for your product or service. Take the time to build trust, and good things will happen organically on their own. About NovationWire NovationWire is a marketing firm that offers customized online press release distribution solutions. These online PR distribution solutions are for PR firms, agencies, organizations & Corporates. It includes e-mail delivery directly to Editors who are targeted to media editors at newspapers, magazines, and broadcast outlets like TV and news/talk radio stations. They also cooperate with significant wire services like ACN Newswire, JCN Newswire, Dow Jones Factiva, Reuters Eikon, Bloomberg Terminal, Yahoo news etc. NovationWire also provides a package to target different regions of the world and too different languages. These regions include Japan, South Korea, Vietnam, Philippines, Indonesia, Malaysia, Philippines, Singapore, China (Hong Kong, Taiwan), Russia, the United States, EU, UK, CA, AU, DE & many other countries. The Press releases could also be translated to English, Korean, Japanese, Chinese, Vietnamese, Thai, Malay, Indonesian, French, Portuguese & Spanish. Media contact Company: NovationWire Contact: Yachin, Marketing Manager Email: pr@NovWire.com Website: http://www.NovationWire.com Skype: skype@NovWire.com Telegram: @NovWire

9 12 月, 2021

Hitachi: Two New FE-SEM Models Launched to Support Data-Driven R&D

TOKYO, Dec 9, 2021 - (JCN Newswire via SEAPRWire.com) - Hitachi High-Tech Corporation ("Hitachi High-Tech") announced today the launch of two cutting-edge FE-SEM(1) models, the SU8600 and SU8700 (hereinafter, "this product line"), that feature new detectors, capabilities, advanced automation, and more. This class of instrumentation is used to observe, measure, define and analyze microstructures across a wide range of fields including semiconductors, life sciences and materials development. To be effective in such fields today, data-driven research and development requiring the acquisition of large data sets is necessary. Therefore, this product line has been designed to support the rapid acquisition of large, high-quality data sets and reduce the effort required by operators through the utilization of next-generation automation.Field Emission Scanning Electron Microscope SU8600(Left), SU8700(Right)Background in the Development of the SU8600 and SU8700FE-SEMs in general are powerful instruments that provide not only high resolution images, but also a plethora of analytical, compositional, and morphological information. These SEMs are used in a wide range of fields including nanotechnology, semiconductors, electronics, life sciences, materials science, and more. Thus, with today's ever expanding application fields, including Materials Integration(2), the need to acquire large amounts of data in a short amount of time with minimal input has become crucial. To address this need, Hitachi has re-envisioned and transformed the implementation of automated functions as well as the design of hardware components in order to support the acquisition of superb data in vast quantities with the utmost efficiency.Features of the SU8700 and SU8600The SU8600 utilizes an ultra-stable cold-field emission source to enable exceptional low-energy imaging for fine structural analysis as well as high-resolution observation of beam sensitive materials like polymers. Conversely, the SU8700 employs a Schottky field-emission source to better address analytical requirements requiring high probe currents such as EBSD(3) analysis on ceramics or metals.This product line has the following key features:1. Automatic Data AcquisitionTraditionally, FE-SEM operators have been required to change and adjust observation conditions on case-by-case basis according to the object or analytical goal. The amount of time it takes to make these adjustments depends on the operator's proficiency and can lead to variations in data quality as well as throughput. Both the SU8600 and SU8700 now integrate functionality to automate many of these adjustment processes, creating simple, stable, high-throughput and repeatable operation.Additionally, as the capability of equipment increases, so does volume of data required and manually collecting these substantial amounts of data can translate to more work for operators. To address this point, the SU8600 and SU8700 can be equipped with an optional "EM Flow Creator" feature, which enables automatic data acquisition according to user-specific conditions and steps. This allows large-scale data sets to be acquired easily, efficiently, and automatically.2. More Information = Better ResultsA multitude of signals can be obtained from almost any SEM, however, this product line permits the display as well as capture of up to six detector signals simultaneously, allowing operators to collect more information in less time.Field of view (FOV) is important for maximizing data acquisition and resolution; therefore, the maximum number of pixels has been expanded(4) to 40,960 x 30,720 pixels, which is 64 times that of existing models(5)! This feature enables detailed evaluation of numerous regions of interest and localized microstructures using just a single image.3. Enhanced Signal Detection CapabilitiesNew optional detectors have been developed for the SU8600 to enhance the observation of topographical and cathode luminescence information. Also, the response speed of the new backscattered electron detector has been improved to increase throughput.Also, the SU8700 specimen chamber is structured in such a way that it allows for EDS(6) analysis at a short WD(7), improving the spatial resolution of the technique and making it possible to thoroughly analyze even smaller features with greater comprehension.Hitachi High-Tech will continue to provide innovative solutions such as this product line for upcoming technology challenges. Furthermore, Hitachi High-Tech will create new social and environmental value by helping our customers be fast-moving, successful in cutting-edge businesses, as well as contributing to cutting-edge manufacturing.(1) FE-SEM: Field-emission scanning electron microscope(2) Materials integration: Comprehensive material technologies that use a combination of theory, experiments, data analysis, simulations, and databases to shorten the development time of materials(3) EBSD: Electron backscatter diffraction. A method used for orientation analysis of crystalline samples(4) This expansion is an optional feature(5) Compared to Regulus Series FE-SEMs(6) EDS: Energy-dispersive X-ray spectroscopy(7) WD: Working distanceAbout Hitachi High-TechHitachi High-Tech, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Analytical & Medical Solutions (manufacture and sales of clinical analyzers, biotechnology products, and analytical instruments), Nano-Technology Solutions (manufacture and sales of semiconductor manufacturing equipment and analysis equipment), and Industrial Solutions (providing high value-added solutions in fields of social & industrial infrastructures and mobility, etc.). The company's consolidated revenues for FY 2020 were approx. JPY 606.3 billion [USD 5.7 billion]. For further information, visit http://www.hitachi-hightech.com/global/ Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

2 11 月, 2021

Regional insurtech Igloo named among “2021 Inclusive Fintech 50”

SINGAPORE, Nov 2, 2021 - (ACN Newswire via SEAPRWire.com) - Regional insurtech, Igloo, was named as one of the winners of the 2021 Inclusive Fintech 50 (IF50) competition, an annual competition hosted by The Center for Financial Inclusion. In its 3rd year, IF50 recognises early-stage Fintechs that are helping low-income customers and micro and small enterprises who are affected by the pandemic and help them rebound, rebuild and recover.Igloo's partnerships with foodpanda in Singapore and Thailand reflect this - in the midst of the Covid-19, Igloo and foodpanda saw a need to provide food delivery riders and their families with a peace of mind as they travel the roads to meet heightened demand from Covid-19 dining restrictions.Last year, Igloo partnered with foodpanda Thailand to introduce an insurance programme that provides free Covid-19 protection for delivery riders in Thailand. In Singapore this year, Igloo introduced PandaCare, a fuss-free and wallet-friendly insurance coverage for delivery riders. PandaCare is specifically designed for gig economy workers and encompasses six benefits: Accidental Death, Accidental Medical Expenses, Accidental Mobile Phone Screen Damage, Daily Hospital Cash, Permanent Total/Partial, Disablement and Temporary Disablement. These benefits also extend to their immediate family members.In August 2021, Igloo also won 'Insurtech Initiative of the Year' at the 6th Insurance Asia Awards. The award recognises Igloo's partnership with PhilPacific Insurance Brokers & Inc (Philinsure) in digitalising PhilInsure's insurance products. This initiative aims to push digitalisation efforts to protect Filipinos and their family members against unpredictable risks such as natural catastrophes like typhoons, flooding, and earthquakes and of course, health risks, including Covid-19."We are honoured to be part of the Inclusive Fintech 50. Understanding the challenges that the COVID-19 pandemic has exerted on the industries, business models, and people's lives, we at Igloo have accelerated technology and digital transformation to help bring support and peace of mind to people during these uncertain times. This achievement is also a validation of our mission to make insurance more accessible in Southeast Asia," said Raunak Mehta, Chief Commercial Officer of Igloo.This year, Igloo has established over 15 key partnerships in diverse industries to make insurance more accessible across the region. In July, the insurtech company partnered with regional leading food delivery platform foodpanda Singapore to launch the insurance product for gig economy workers. In September, Igloo successfully launched partnerships with leading e-Wallet platforms in the Philippines GCash and DANA in Indonesia to provide online shopping insurance product (PH) and phone screen protection insurance product (ID). The company aims to launch more strategic collaborations with partners in different industries ranging across e-commerce, lifestyle, and health tech by the end of this year.About IglooIgloo, previously known as "Axinan", is the first full-stack insurtech firm to emerge from Singapore. It has offices in Singapore, Indonesia, Thailand, the Philippines, and Vietnam, and tech centres are located in China. With a mission of making insurance accessible for all, the firm leverages big data, real-time risk assessment, and end-to-end automated claims management to create B2B2C insurance solutions for platform companies and insurance companies. Igloo's insurance solutions enable companies to eliminate their exposure to operational risk, create new revenue streams, and optimize and enhance existing products and services. In April 2020, Igloo successfully closed its Series A+ funding round worth US$8.2 million, bringing its total funding to US$16 million from global investors.Igloo is led by a core team that comprises top talent from the technology and insurance industries hailing from global corporations including Facebook, Grab, Flipkart, Garena, Manulife, Shopee, Yahoo! and Zalora. For more information, please visit https://www.iglooinsure.comMedia QueriesPRecious Communications for Iglooigloo@preciouscomms.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

27 10 月, 2021

Dynasty Holds Series of Activities for Autumn Food & Drinks Fair, Launches New Marketing Strategies

HONG KONG, Oct 27, 2021 - (ACN Newswire via SEAPRWire.com) - Dynasty Fine Wines Group Limited (Stock Code: 828), a premier winemaker in China, held a series of activities in relation to the 105th China Food & Drinks Fair during 15 - 21 October in Tianjin. These activities include the participation in the Autumn Food & Drinks Fair, and the organisation of the Pre-Fair "Wineseer" Wine Exhibition, Dynasty Pre-Fair Plant Open Day, Grand Opening Ceremony for the new premises of its National-level Technology Centre, Dynasty Dry White Wines Night, and a wine tasting event for Dynasty air dry wines and Dynasty brandy along with the world's premier wines. These events received enthusiastic response from distributors. Another highlight was a press conference to announce its latest marketing model and strategies and to unveil two new product series targeting young consumers, namely Sweet Heart and Pleasant Color.Dynasty participates in the 105th China Food & Drinks FairDynasty's new product series - Sweet HeartDynasty's new product series - Pleasant ColorDynasty said, "Since Dynasty launched the market demand-oriented '5+4+N product strategy' last year and subsequently completed the upgrade of its organisational structure, the unaudited consolidated revenue in the first half of this year nearly doubled to approximately HK$179.6 million, and the successful results are obvious to all. In the future, in line with the industry development trend, Dynasty will strengthen its presence in mass-market and mid-range products as well as those targeted at young consumers. We will also expand our distribution channels, with the aim to deploy 100,000 point-of-sales, add 1,000 distributors and vigorously develop new channels via retail platforms during the next three years, so as to seize the opportunities from the growing consumption market of young adults and strive to achieve the annual sales target exceeding RMB1 billion in that time".To realise the objective of rearch its point-of-sales network expansion target in three years, Dynasty will further map out its product, channels, and retail sales by expanding the circles of marketing, pursuing advances in business prospecting as well as developing new retail channels. Dynasty will also continue to focus on traditional e-commerce platforms such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation across its brand, product categories, and business systems, procedures and models via new retail platforms, including Weibo, RED (Xiaohongshu app), Kuai (Kuaishou app) and TikTok (Douyin app). Such efforts will facilitate the Group's brand communications so that it can continue to gain the attention of mainstream consumer groups and demographic segments, and enhance effective market penetration of the Group's products targeted at young consumers.In addition, Dynasty will prioritise three "New"s so as to capture the young adult consumer market from three aspects. The first is "new products". Dynasty will launch products with a sweeter and more subtle taste and with packaging accenting a youthful Chinese style. The second is "new channels". While insisting to integrate the manufacturing, distribution and retail businesses into one, Dynasty will continue to focus on ready-to-drink channels, beer sales channels and Business & Customer-end catering channels. The third is "new prices". Dynasty will price its new products by focusing more on the mid-range to mass-market young market segments. Moreover, Dynasty has also noted the huge room for growth in dry white wines as their consumption is far lower than that of dry red wines in China. Hence, the Group will vigorously develop the dry white wine series within which it boasts strong advantages. At its new marketing model and strategy press conference, Dynasty unveiled two new product series which are focused on the entry-level product price range and targeted at young consumers, namely Sweet Heart and Pleasant Color. The former mainly offers white wines, opening a new chapter for the Group's product rejuvenation strategy.In addition, Dynasty has recently held a grand opening ceremony for the new premises of its National-level Technology Centre, which had been granted approval to set up a post-doctoral work station last year. The work station is initially researching the selection of distinctive muscat yeast in order to brew more mellow and delicious wines. The completion of the new premises at the National-level Technology Centre will further promote the Group's research and development of new products as well as new winemaking techniques. Looking ahead, the Group will firmly respond to the needs of consumers by developing and innovating its series of wines and offering more distinctive products. It will also strive to demonstrate its brand vitality via diversified channels while realising brand and product rejuvenation. Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

12 10 月, 2021

NEC Wins 2021 Leading Lights Award for ‘Best New 5G Core Product’ and ‘Best New Open RAN Product’

TOKYO, Oct 12, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (TSE: 6701) today announced that it has been named a winner in the Light Reading 2021 Leading Lights Awards program in the 'Best New 5G Core Product' for its cloud-native 4G/5G Converged Core and 'Best NEW Open RAN Product' category for its 5G massive MIMO radio units.The Leading Lights is one of the telecom industry's most prestigious awards programs, recognizing top companies and executives for their outstanding achievements in next-generation communications technology, applications, services, strategies and innovations. The Leading Lights winners were announced during an online awards ceremony on October 8, 2021.'Best New 5G Core Product' - NEC's 4G/5G Converged CoreNEC is a pioneer in cloud-native 5G core (5GC), starting with the launch of several private 5G services using our 5GC SaaS on AWS, announcing commercial availability of the world's first 5G cloud native mobile core* and its market-leading User Plane Function (UPF) performance at 640Gbps /server. With key highlights such as stateless, microservice-based cloud-native architecture, platform-agnostic operation, and high performance, NEC's 5GC enables operators to benefit from shorter time to market, and immediate monetization through a variety of use cases (from B2C to B2X). 5GC can be deployed from micro private instances on a single server to macro multi million users on clouds in a variety of scenarios, from on-premise COTS servers, to private, public or hybrid cloud environments.'Best New Open RAN Product' - NEC's 5G Radio Unit (RU)NEC is the first and only massive MIMO (mMIMO) Open RAN RU vendor commercially deployed at scale in dense, urban environments*. This signature product line announced for commercial general availability this year featuring advanced digital beamforming brings dramatic capacity while preserving open and flexible deployment options afforded by Open RAN. Our 5G massive MIMO radio units have recently been selected by Vodafone for implementation, as well as Telefonica and Deutsche Telekom for live network integration trials."Congratulations to NEC for being selected as a Leading Lights winner," said Light Reading Editor-in-Chief Phil Harvey. "The award demonstrates that NEC not only had a great year, but is on a trajectory to continue to make a difference in the global communications industry. We look forward to seeing what they do next.""We are grateful to Light Reading for recognizing NEC's 4G/5G Cloud-Native Converged Core and Open RAN 5G massive MIMO RUs as leading products in the industry," commented Patrick Lopez, Global VP of Product Management for 5G Products, NEC. "NEC is a pioneer and leader in developing end-to-end Open 5G solutions which bring tremendous value and innovation to the market. As an industry trailblazer of Open 5G, NEC is keen to continue its investment and to drive the next generation networks across the world."Light Reading's reputation for fiercely independent analysis of the people, products and companies it covers makes this among the most credible and authoritative awards programs in the industry. Leading Lights judging was conducted by Light Reading's editors with input from the analyst team at Heavy Reading. (http://www.heavyreading.com). For a full list of winners, read Light Reading's blog (https://www.lightreading.com/opticalip/leading-lights-2021-winners-video/v/d-id/772632).*Source: NEC researchAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

18 9 月, 2021

VOOPOO : DRAG X PRO Global Release, TPP X POD Brings Highly Powerful Experience

SHENZHEN, CHINA, Aug 25, 2021 – (ACN Newswire) – VOOPOO’s international new product launch came on August 18 as scheduled, during which annual new product DRAG X PRO was officially released. With VOOPOO constantly pushing the boundaries of performance and design, DRAG X PRO is meeting the diverse needs of its users and bringing innovative experiences to consumers around the world. The newly developed TPP X POD is the powerful guarantor for the stable operation of DRAG X PRO. On one hand, two atomizing cores, 40W and 80W, not only optimize the stable output of high power but also meet the users’ pursuit of high performance and big clouds. On the other, TPP X POD has achieved “single-hole and dual-mesh” atomization and successfully applied it in both new products. With the support of a large aperture and double heating wires, TPP X POD has greatly improved the atomization efficiency and comprehensive experience compared with the previous generation. DRAG X PRO atomizer core is highly adaptable, to meet the needs of discerning vapers who focus on taste variability. In addition to the TPP X POD delivered with the product, it is compatible with all TPP/PNP atomizers. Users can also combine atomizers according to their preferences, for they only need to replace the PNP POD when using the PNP atomizer. Multi-Functional, All-Round Technology Upgrade DRAG X PRO uses One Button Switch technology, allowing users to experience the professional performance instantly with a single flick of the button. The newly designed GENE.FAN 3.0 Chip has an overall performance improvement of 20% by the previous generation. The 5-80/100W switch fades smoothly while the SMART, RBA, and TC modes can be accessed freely. Besides a high-power cap and an external replaceable battery, DRAG X PRO also focuses on a highly powerful taste. With more attention paid to detailed design, DRAG X PRO has an exquisite body and a conveniently rechargeable battery. Both versions come with an 8.5V boost mode, which optimizes the performance output even when the battery runs out, making the stable flavour linger on. The air hole and 360-degree infinite airflow system specially designed for the MTL experience vividly epitomize the brand spirit of VOOPOO driven by innovation. At present, VOOPOO has four major product lines – DRAG, VINCI, ARGUS, and V – which are available in 70 countries and regions across North America, Europe, and Southeast Asia. VOOPOO will adhere to atomization technology R&D and high-quality vape as the original aspiration, strengthen the exchanges and cooperation in technology, brand, supply chain, and other fields, and promote the innovative and constructive development of the industry. WARNING: This product uses e-liquid products containing nicotine. Nicotine is an addictive chemical. These products are intended for adult smokers of legal purchase age only. Contact VOOPOO:Official Website: https://www.voopoo.com/Instagram (global): https://www.instagram.com/voopoo_global/Instagram (tech): https://www.instagram.com/voopootechofficial/Facebook: https://www.facebook.com/Voopootech/Tiktok: https://www.tiktok.com/@voopoo_indonesia?lang=enBusiness email: sales@voopoo.com

29 6 月, 2021

KGISL Completes Acquisition of AETINS, Expands Expertise in the Insurance Space

Singapore / Malaysia, Jun 29, 2021 - (ACN Newswire via SEAPRWire.com) - KG Information Systems Private Limited (KGISL), a global IT services, consulting, and business solution provider, today announced the acquisition of AETINS Sdn. Bhd., (199801000924), through its wholly-owned subsidiary in Malaysia, KG Information Systems Sdn. Bhd. (201301013805). The acquisition is a part of KGISL's growth strategy in the InsurTech space.Prassadh Shanmugam, Director and Chief Executive Officer, KGISLAETINS brings aboard an exceptional range of insurance solutions for Life, General and Takaful bundled with an unmatched domain expertise. AETINS' Core Insurance Product and Solutions are well known in the market and are market leading. The company serves a vast clientele of insurance firms in the Asia Pacific, Middle East, and North Africa. The people, products, and solutions from AETINS would be leveraged in expanding KGISL's footprint in the InsurTech space.KGISL has its market presence in the Malaysia InsurTech space since 2006 and has grown as a market leader with its Point of Sale (PoS) and Claims Management Solution for the Non-Life Insurance segment. The acquisition of AETINS will now bring in Core Insurance Product and Insurance Solution Framework (ISF) into KGISL's product offerings and opens doors to enter the wider Asia Pacific, Middle East, and Africa markets covering the Life, Non- Life and Takaful Insurance segments.Mr. Prassadh Shanmugam, Director and Chief Executive Officer, KGISL commenting on the acquisition said, "I am super excited about this acquisition. AETINS' Core Insurance products, Takaful offerings and good presence in the Middle East market are the missing pieces in KGISL's Insurance offerings. It would have taken years for us to build this capability, so the acquisition is a perfect fit for KGISL. The employees of AETINS share the same integrity, culture and value systems of KGISL, so the integration will also be smooth and quick."Commenting on the acquisition, Dr Ashok Bakthavathsalam, Managing Director, KGISL said, "The acquisition brings together two leading InsurTech players in pursuit of a common mission, centred on providing the best value for customers, organisation and employees. With able leadership and a go-getter team, KGISL has been on a fast growth trajectory, clocking a five-fold growth in the last four years. This acquisition adds momentum, and I am confident that our growth will be even faster in the next 3 years."About KGISL: www.KGISL.com/gssKG Information Systems Private Limited (KGISL) is a global IT Services, Consulting and Business Solutions provider in the BFSI space. KGISL offers Software Products, Solutions and Services in Intelligent Automation, ERP (SAP), CRM, Business Intelligence and Analytics, Quality Engineering, IT Infrastructure Management and Application Development. KGISL has offices in India, US, Malaysia, Singapore, Australia and Thailand.KGISL is part of the $750 million business conglomerate KG Group with interest in Textiles, Engineering, Healthcare, Education, Real Estate, Entertainment, Software and Business Support Services. The Group employs over 25000 people and is known for its philanthropic services to the community for over 8 decades. About AETINS: www.aetins.com/ AETINS, established in 1998, is a single end-to-end Insurance and Takaful Solution provider that covers all lines of business: Individual Life, Group Life, Investment Linked and General. It spans across functions like illustration, quotation, new business, policy servicing, claims, agency management, commission and benefits, accounting and services. Our business is to help Insurance and Takaful Companies to strategize and operate by leveraging on Information Technology, a key enabler to achieve transformational growth through Operational Excellence and Innovation.For further information, please contact:KGISL: Sampathkumar S | sampathkumar.s@KGISL.com | +91 9940069884Adfactors PR (India): Bhargav TS | bhargav.ts@adfactorspr.com | 9884883350Shamitha Hegde | shamitha.hegde@adfactorspr.com | 9003107361 Adfactors PR (Singapore): Namrata Sharma | namrata.sharma@adfactorspr.com | +65 8138 3034 Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)

25 6 月, 2021

NEC and MTI enter strategic partnership to accelerate Open RAN deployments globally

TOKYO, Japan and HSINCHU, Taiwan, Jun 25, 2021 - (JCN Newswire via SEAPRWire.com) - NEC Corporation (NEC; TSE: 6701), a leader in the integration of IT and network technologies, and Microelectronics Technology Inc. (MTI; TAIEX: 2314), a leading network RF solutions provider, today announced a collaboration to enhance the Open RAN ecosystem with a variety of radio options to cater to global 4G and 5G markets.This strategic partnership is intended to provide a broader Open RAN product offering for Communication Service Providers (CSPs) and enable various use cases ranging from rural to urban areas, with network configurations and performance profiles, such as non and massive MIMO.Under this agreement, NEC and MTI will jointly bring to market radio units to meet the increasing need for more Open RAN radios. NEC and MTI will continue to meet the high-quality standards required for Tier-1 operators deploying Open RAN networks across the globe.In response to the market demands for supply chain diversification ensuring carrier-grade performance, reliability and availability, NEC has implemented a variety of different options to increase its Open RAN and disaggregated product portfolio. This strategic partnership extends NEC's Open RAN product lineup, addressing a vast market opportunity."NEC is an industry leader in open and disaggregated networks, demonstrating its capabilities in integrating end-to-end Open RAN solutions," said Allen Yen, Chairman and CEO of MTI. "MTI is excited to be one of NEC's strategic partners to jointly address the need for open, high performance, high quality 5G radio products.""An open, disaggregated 5G network ecosystem promises to drive transformation throughout the industry," said Shigeru Okuya, Senior Vice President, NEC Corporation. "With this firm and strategic partnership with MTI, NEC reinforces its commitment to accelerate commercial Open RAN deployments and to deliver more value to its customers."About MTIMicroelectronics Technology Inc. (MTI) is a high-technology company that has specialized in wireless communication product development, manufacturing, and global sales for more than 35 years. Based on core competency in RF/ Microwave, MTI has established a leading position in the fields of Remote Radio Heads, Microwave Radios, Satellite Transceivers and ODUs, Broadband Wireless access products, and Radio Frequency Identification (RFID) readers and modules. With this excellent record of accomplishment, MTI has established valued, long-term partnerships with world-leading partners.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2021 JCN Newswire. All rights reserved. (via SEAPRWire)

22 6 月, 2021

Global IT Consultancy Xebia Acquires coMakeIT to Support Clients’ Continuous Innovation

Hilversum, the Netherlands, 22 June 2021 - Xebia, the global IT consultancy firm, has acquired software product engineering company coMakeIT to support clients' continuous innovation and business growth.coMakeIT, founded in the Netherlands in 2006, helps product and software companies thrive by providing software product expertise, people and tools needed to meet ambitious objectives. Today, the company's primary focus is on product software companies creating the right mix of technology and teams support with the right talents so that its clients can achieve sustainable growth. CoMakeIT has profound knowledge of software development, product engineering, application modernization, digital transformation, and recruitment and operates from offices in the Netherlands, the UK, India, and Australia.Xebia is a fast-growing digital leader known for helping companies worldwide digitally transform by offering high-quality IT consultancy from its offices in the Netherlands, India, the UK, US and Dubai. The company has successfully launched several brands and continues to expand in line with its 'buy and build' strategy: partnering with thought leaders to gain additional footing in the digital space together. With coMakeIT, Xebia looks forward to expanding its managed services capability and having the resources to accelerate its clients' software development.Steven ten Napel, CEO and founder coMakeIT: "We are extremely value-driven. Just like Xebia, at coMakeIT, it's all about 'people first.' Our company culture and field of work are very similar, which makes us a perfect match. Together, we will soon be able to better assist clients in overcoming scalability issues, implementing modern technology, and realizing growth."Anand Sahay, CEO Xebia Global Services: "Xebia is an established leader in the Digital transformation, Software Engineering, Cloud, DevOps and Architecture space. Acquiring coMakeIT will help Xebia address the cloud-native and platform development needs of the ISV market and grow in that space globally. Together with coMakeIT, we clearly see the complementary ability to create future-ready products for our ISV customers and also develop innovative software for these platforms to help ISV's customers' needs. This creates a very strong proposition for ISVs and our ability to partner with them." Vipul Baijal, Country Head - Xebia USA: "As the ISV market is moving towards the next phase of transformation and looking to solve scalability issues and platform challenges Xebia's acquisition of coMakeIT creates a unique value proposition to our ISV customers in North America and globally to create future-ready and innovative products and solutions."The right technology and the right talents are crucial for growth in a digital world. Acquiring coMakeIT will strengthen Xebia's long-term relationships with clients through comprehensive managed services, and coMakeIT will gain access to Xebia's in-depth knowledge of all digital transformation domains. Besides sharing the same values, both originally Dutch companies have experience expanding their presence to India, for example, and will jointly continue to help businesses grow worldwide.About XebiaXebia is a leading IT Consulting and Digital Technology company committed to delivering innovation and business excellence across the globe. It delivers digital solutions to global leaders for transforming their IT and Business Operations.With nearly two decades of experience, it enables its clients through their digital journey by enabling them with informed decision-making through process level enhancements, intelligent data solutions, enhance their customer experience & journeys with new-age solutions and help strengthen their core with modern technologies such as AI/ML/Robotics, Microservices, Cloud-native apps and agile at scale to deliver unprecedented levels of performance. For more information, please visit us at http://www.xebiaus.comAbout coMakeITHeadquartered in Baarn, Netherlands, and with offices in Australia, UK, and India, coMakeIT helps software businesses and enterprises to accelerate their product innovation, modernize aging applications, and productize best practices into new software IP. For more information, please visit us at https://www.comakeit.comFor media queriesEmail: usa@xebia.com Copyright 2021 ACN Newswire. All rights reserved. (via SEAPRWire)